FDA Patient Meeting On Huntington’s, Parkinson’s: No News Is Good News
Patient-focused drug development meetings address 'soft symptoms' and reimbursement challenges as FDA says it's familiar with most concerns aired by participants.
You may also be interested in...
CDER Director Woodcock says agency should write down its definition of a surrogate endpoint, but industry and academics will have to help with requirements for biomarker approval.
FDA wants to advance PRO projects through the user fee reauthorization, but ironically is having difficulty quantifying how much support it might need.
Rivipansel, partnered with GlycoMimetics, is one of the most advanced drugs in Pfizer’s rare disease pipeline. Phase III studies have been delayed, however, due to a manufacturing issue impacting supply.